Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The standardized prevalence rates of DM in FHBL1 were similar to those of the reference population, with a prevalence rate of 8.2 and 9.2%, respectively, while FHBL2 showed a 4.9% prevalence of DM.
|
27804036 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we assess the available evidence for the association of PCSK9 status with the incidence and control of DM in preclinical and clinical studies, and identify molecular mechanisms regulating PCSK9 expression in the diabetic state.
|
28111330 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes.
|
29180351 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
|
29377473 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.
|
30487231 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Loci that encode targets of emerging LDL-C lowering drugs do not associate with dysglycemia, and this provides provisional evidence that new LDL-C lowering drugs (such as PCSK9 inhibitors) may not influence risk of diabetes.
|
26946290 |
2016 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCSK9 inhibition with evolocumab significantly reduced cardiovascular risk in patients with and without diabetes.
|
28927706 |
2017 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
350 patients (62 ± 11 years old, 58% men, 22% with diabetes mellitus) with different concomitant lipid lowering therapies, and in whom PCSK9-I treatment was indicated, received either evolocumab (140 mg) or alirocumab (75 or 150 mg).
|
30910670 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We observed suggestive associations with the diabetes risk variant rs7961581 (p = 0.038; between TSPAN8 and LGR5) and rs5215 (p = 0.043; KCNJ11), the LDL risk variant rs11206510 (p = 0.045; PCSK9), as well as the AF risk locus ZFHX3.
|
24135527 |
2013 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study.
|
28347654 |
2017 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This post-hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY Phase 3 trials.
|
29802688 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes.
|
31272931 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Although genetic variants associated with lower levels of LDL-C are also associated with an increased NOD risk, clinical trials with lipid-lowering drugs other than statins, namely ezetimibe or monoclonal antibodies against PCSK9, did not observe an increase of developing diabetes.
|
31029825 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We studied the effects of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on fasting plasma glucose, glycated hemoglobin, weight, and new-onset diabetes mellitus.
|
28844508 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The ECDP writing committee judged that these new data did not warrant changes to the decision pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C ≥190 mg/dL not due to secondary causes.
|
28886926 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status.
|
30183102 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This article reviews the underlying aetiology and pathophysiology of this dyslipidaemia and atherosclerosis in those with diabetes, provides insights from epidemiological and genetic studies, and current cardiovascular risk reducing interventions including novel therapies such as PCSK-9 inhibitors.
|
31002453 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariable Cox regression analysis showed that the third versus the first tertile of PCSK9 (hazard ratio: 1.640; 95% confidence interval: 1.117 to 2.407; p = 0.012), female sex, age, diabetes, smoking, heart failure, previous cerebrovascular and cardiac events, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associated with CVEs.
|
28911508 |
2017 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Interestingly, compared with ezetimibe, which was actively used as lipid-modifying therapy in the control group, PCSK9-mAbs seem to have a lower risk of incident diabetes (RR 0.60, 95% CI 0.37-0.99; p = 0.04).
|
31823301 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk.
|
27908689 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
There is an emerging role for the recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in diabetes, as these agents further reduce serum cholesterol and clinical cardiovascular events beyond the maximum tolerated statin therapy.
|
28871349 |
2017 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients with stable CAD, low PCSK9 plasma levels are associated with a particular metabolic phenotype (low HDL cholesterol, the metabolic syndrome, obesity, insulin resistance and diabetes) and diffuse non-obstructive coronary atherosclerosis.
|
31672148 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Use of these PCSK9 inhibitors was not associated with increased risk of neurocognitive adverse events (P = 0.91), liver enzymes elevations (P = 0.34), rhabdomyolysis (P = 0.58), or new-onset diabetes mellitus (P = 0.97).
|
31270529 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In studies reporting data on MACE and mortality separately for individuals with and without diabetes, the effect of PCSK-9 did not appear to be affected by diabetes.
|
30485622 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease.
|
30786741 |
2019 |